Gastric Emptying Delay: Slows down food transit through the upper gastrointestinal tract, maintaining a prolonged sensation of fullness
A 2025 Phase I trial (Lee & Burgess, 2025) demonstrated that IV BPC-157 doses up to 20 mg were tolerated in healthy volunteers with no serious adverse events
These sites have been specifically validated through clinical trials to ensure consistent drug absorption, with no clinically meaningful differences in exposure observed between injection sites
Bilchick notes, Even with these great ablation tools and techniques associated with the emergence of pulsed field ablation for Afib, if there is an underlying metabolic or inflammatory condition thats promoting more arrhythmia, then being on these medications can help mitigate that and improve long-term success rates. What Could This Mean for You
The guidance from manufacturers, clinical pharmacologists, and experienced prescribers all converge on the same recommendation